Evidence map›Paper›PMID 41367635›Full record

ArticleInternational medical case reports journal2025

Moving Through Genetic Alterations and PD-L1 Expression in High-Grade Fetal Adenocarcinoma of the Lung: A Case Report and Literature Review.

YunQiu Xu, KangJian Dai, Wei Chen, Haifan Wu, Peifeng Lin

Abstract readCase Reports
In one paragraph

Article in International medical case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

YunQiu XuDepartment of Cardiothoracic Surgery, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People's Republic of China.ORCID 0000-0002-5591-1632
KangJian DaiDepartment of Cardiothoracic Surgery, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People's Republic of China.
Wei ChenDepartment of Cardiothoracic Surgery, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People's Republic of China.
Haifan WuDepartment of Cardiothoracic Surgery, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People's Republic of China.
Peifeng LinDepartment of Cardiothoracic Surgery, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People's Republic of China.ORCID 0009-0009-7510-9696

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung cancer, the most common malignancy in humans, can be classified into a wide range of subtypes and molecular variants. Fetal adenocarcinoma of the lung (FLAC) is an infrequent subtype of lung adenocarcinoma with distinct histological characteristics. However, its incidence is extremely low (0.1-0.5% of primary lung cancers), and its biological features remain poorly understood. In the era of immunotherapy and targeted therapy, characterizing the genetic alterations of FLAC is essential for developing personalized treatment strategies and improving patient outcomes. Here, we report the genetic alterations and PD-L1 expression in a patient with high-grade FLAC (H-FLAC) and review the relevant literature, This is one of the few reported cases describing PD-L1 expression and TP53 mutation status in H-FLAC. Case Manifestations: A 57-year-old man with a 30-year history of smoking presented to our hospital with persistent cough, sputum, and chest tightness for 30 years, which had worsened for 1 month. Computed tomography (CT) of the chest revealed an irregular nodule in the posterior segment of the upper lobe of the left lung. The patient underwent posterior resection of the left upper lung apex, and postoperative pathology suggested H-FLAC with a tumor stage of pT Conclusion: This case study provides an opportunity to better understand H-FLAC, whose genetic alterations have not been well characterized, and to identify valuable molecular markers for potential targeted therapies. We conducted gene sequencing and PD-L1 expression testing, which are helpful for H-FLAC research.

Indexed as

fetal adenocarcinoma of the lunggenetic variantprogrammed death ligand-1TP53

Identifiers

PMID41367635
PMCPMC12682920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.